Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers

Angela Cheng-Lai, William H. Frishman

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Angiotensin-converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.

Original languageEnglish (US)
Pages (from-to)477-491
Number of pages15
JournalJournal of Clinical Pharmacology
Volume38
Issue number6
StatePublished - Jun 1998

Fingerprint

Calcium Channel Blockers
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Pharmacokinetics
Costs and Cost Analysis
Captopril
Drug Interactions
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers. / Cheng-Lai, Angela; Frishman, William H.

In: Journal of Clinical Pharmacology, Vol. 38, No. 6, 06.1998, p. 477-491.

Research output: Contribution to journalArticle

@article{0c64ad7b332643d4ab8414f1d0d86ba1,
title = "Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers",
abstract = "Angiotensin-converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.",
author = "Angela Cheng-Lai and Frishman, {William H.}",
year = "1998",
month = "6",
language = "English (US)",
volume = "38",
pages = "477--491",
journal = "Journal of Clinical Pharmacology",
issn = "0091-2700",
publisher = "SAGE Publications Inc.",
number = "6",

}

TY - JOUR

T1 - Use of angiotensin-converting enzyme inhibitors as monotherapy and in combination with diuretics and calcium channel blockers

AU - Cheng-Lai, Angela

AU - Frishman, William H.

PY - 1998/6

Y1 - 1998/6

N2 - Angiotensin-converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.

AB - Angiotensin-converting enzyme (ACE) inhibitors have earned an important place in medical therapy since their discovery about two decades ago. This family of drug has grown tremendously since the introduction of captopril in 1981. There are currently more than 14 ACE inhibitors in the world and 9 are available in the United States. Although these agents share many similarities, they differ in their pharmacokinetic properties, approved indications, and cost. This paper provides guidance for selection of ACE inhibitors by examining the pharmacokinetics, pharmacodynamics, drug interactions, adverse effects, and cost of these agents. Combination products of ACE inhibitors with either diuretics or calcium channel blockers also are reviewed.

UR - http://www.scopus.com/inward/record.url?scp=0031750131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031750131&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 477

EP - 491

JO - Journal of Clinical Pharmacology

JF - Journal of Clinical Pharmacology

SN - 0091-2700

IS - 6

ER -